Search | Clinical Trials Finder

Conditions: Necrotizing Pancreatitis
Interventions: Using ABTHERA Advance without a Wittmann Patch; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Years and older
Enrollment: 3 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
Interventions: TriVerity; Diagnostic Test
Lead sponsor: Inflammatix; Industry
Eligibility: 18 Years and older
Enrollment: 1,441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • Los Angeles, California • Sacramento, California + 22 more

Conditions: Intraabdominal Infections
Interventions: Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: San Diego, California • Springfield, Massachusetts

Conditions: Complicated Intra-abdominal Infections (cIAI)
Interventions: IV Eravacycline 2mg/kg, IV Eravacycline 1.5mg/kg; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 2 more

Conditions: Abdominal Abscess
Interventions: Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo; Drug · Other
Lead sponsor: Paolo Goffredo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Complicated Intra-Abdominal Infection
Interventions: Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 7 Days to 17 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 6 more

Conditions: Intra-abdominal Infections
Interventions: LYS228, Standard of care therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Somers Point, New Jersey

Conditions: Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions: Nutrition Ecosystem pathway, Comparator; Combination Product · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infections, Intestinal
Interventions: Drug: GSK2251052, Meropenem, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Mobile, Alabama • Long Beach, California • Torrance, California + 9 more

Conditions: Sepsis
Interventions: Frailty Measurements, Modified Minnesota Leisure Time Activities, Computed tomography morphometrics, Mobility Monitors; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Complicated Intra Abdominal Infections
Interventions: ampicillin and metronidazole and gentamicin, ampicillin and gentamicin and clindamycin, gentamicin and Piperacillin- tazobactam, standard of care antibiotics and metronidazole, metronidazole, clindamycin, or piperacillin-tazobactam; Drug
Lead sponsor: Michael Cohen-Wolkowiez; Other
Eligibility: Up to 120 Days
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 45
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 35 more

Conditions: Acute, Perforated Appendicitis
Interventions: Irrigation with PVI, Usual care; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Perforated Appendicitis
Interventions: PVI, Usual Care; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions: ATM-AVI, MTZ, MER, COL; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Tucson, Arizona • Torrance, California • Springfield, Illinois

Conditions: Complicated Intra-abdominal Infection
Interventions: TP-434, Ertapenem, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Long Beach, California • Denver, Colorado • Detroit, Michigan + 2 more

Conditions: Surgical Wound Infection, Wound; Abdomen, Abdominal Wall, Surgery
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-201 and metronidazole, Meropenem; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Springfield, Illinois • Boston, Massachusetts • Robbinsdale, Minnesota + 1 more

Conditions: Pancreatic Trauma, Pancreatic Duct Injury, Pancreas Necrosis, Pancreas Cyst, Pancreas; Fistula, Pancreas Abscess, Intra-Abdominal Abscess, Anastomotic Leak, Pancreas Injury
Interventions: Exploratory laparotomy; Procedure
Lead sponsor: Kern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Complicated Intra-abdominal Infections
Interventions: Ceftazidime -avibactam, Meropenem, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Orange, California • San Diego, California • Toledo, Ohio + 1 more

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Orange, California • Torrance, California • Aurora, Colorado + 8 more

Conditions: Abdominal (ABD) Infection
Interventions: Arm 1: Routine Care, Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection; Other
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 18 Years and older
Enrollment: 198,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 101
States / cities: Riverside, California • San Jose, California • Thousand Oaks, California + 79 more

Conditions: Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
Interventions: tigecycline, ceftriaxone sodium + metronidazole; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 46
States / cities: Mobile, Alabama • Laguna Hills, California • Los Angeles, California + 38 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Complicated Intra-abdominal Infections
Interventions: ceftazidime/NXL104 + metronidazole, meropenem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 9
States / cities: Los Angeles, California • Palm Springs, California • Detroit, Michigan + 5 more

Search by objective public record fields.

ABTHERA ADVANCE™ Use Without Wittman Patch

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Antibiotic Irrigations for Intra-Abdominal Drains

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty

Antibiotic Safety (SCAMP)

Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study

APPI-Cost Trial for Perforated Appendicitis

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Surgical Site Infection Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy at Initial Closure

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

A Retrospective Analysis of Pancreatic Injuries and Treatment Outcomes

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

INSPIRE Trial for Abdominal Infections

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections